Influenza Vaccine Effectiveness in the United States during the 2016-2017 Season

Clinical Infectious Diseases

Volumn 68, Issue 11, 2019, Pages 1798-1806

  Flannery, Brendan ^a   Chung, Jessie R ^a   Monto, Arnold S ^b   Martin, Emily T ^b   Belongia, Edward A ^c   McLean, Huong Q ^d,e   Gaglani, Manjusha ^d   Murthy, Kempapura ^f   Zimmerman, Richard K ^f   Nowalk, Mary Patricia ^g   Jackson, Michael L ^g   Jackson, Lisa A ^a   Rolfes, Melissa A ^a   Spencer, Sarah ^a   Fry, Alicia M ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c MARSHFIELD CLINIC   (United States)

^d SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^e TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^f UNIVERSITY OF PITTSBURGH   (United States)

^g KAISER PERMANENTE   (United States)

Author keywords

Influenza vaccine; vaccine effectiveness

Indexed keywords

INFLUENZA VACCINE; INACTIVATED VACCINE; VACCINE;

ACUTE DISEASE; ADOLESCENT; AGED; ARTICLE; BODY HEIGHT; BODY WEIGHT; CHILD; COUGHING; DRUG EFFICACY; ELECTRONIC MEDICAL RECORD; FEMALE; GROUPS BY AGE; HEALTH CARE FACILITY; HEMAGGLUTINATION INHIBITION TEST; HIGH RISK PATIENT; HUMAN; ICD-10; INFANT; INFLUENZA A (H3N2); INFLUENZA B; INFLUENZA VACCINATION; INFLUENZA VIRUS; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MICHIGAN; MULTICENTER STUDY; NOSE SMEAR; OUTPATIENT; OUTPATIENT CARE; PENNSYLVANIA; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEASONAL INFLUENZA; TEXAS; THROAT CULTURE; UNITED STATES; VIRUS; WASHINGTON; WISCONSIN; ADULT; CLINICAL TRIAL; IMMUNIZATION; IMMUNOLOGY; INFLUENZA; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H3N2); INFLUENZA B VIRUS; MIDDLE AGED; PRESCHOOL CHILD; SEASON; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNIZATION; INFANT; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; OUTPATIENTS; SEASONS; TREATMENT OUTCOME; UNITED STATES; VACCINE POTENCY; VACCINES, INACTIVATED; YOUNG ADULT;

EID: 85066918768     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciy775     Document Type: Article

References (30)

1. Flannery B, Zimmerman RK, Gubareva LV, et al. Enhanced genetic characterization of influenza A(H3N2) viruses and vaccine effectiveness by genetic group, 2014-2015. J Infect Dis 2016; 214:1010-9.
2. Zimmerman RK, Nowalk MP, Chung J, et al. 2014-2015 influenza vaccine effectiveness in the United States by vaccine type. Clin Infect Dis 2016; 63:1564-73.
3. Belongia EA, Simpson MD, King JP, et al. Variable influenza vaccine effectiveness by subtype: A systematic review and meta-analysis of test-negative design studies. Lancet Infect Dis 2016; 16:942-51.
4. Belongia EA, Skowronski DM, Mc Lean HQ, Chambers C, Sundaram ME, De Serres G. Repeated annual influenza vaccination and vaccine effectiveness: Review of evidence. Expert Rev Vaccines 2017; 16:1-14.
5. Gaglani M, Spencer S, Ball S, et al. Antibody response to influenza A(H1N1) pdm09 among healthcare personnel receiving trivalent inactivated vaccine: Effect of prior monovalent inactivated vaccine. J Infect Dis 2014; 209:1705-14.
6. Jackson ML, Chung JR, Jackson LA, et al. Influenza vaccine effectiveness in the United States during the 2015-2016 season. N Engl J Med 2017; 377:534-43.
7. Mc Lean HQ, Thompson MG, Sundaram ME, et al. Influenza vaccine effectiveness in the United States during 2012-2013: Variable protection by age and virus type. J Infect Dis 2015; 211:1529-40.
8. Ohmit SE, Thompson MG, Petrie JG, et al. Influenza vaccine effectiveness in the 2011-2012 season: Protection against each circulating virus and the effect of prior vaccination on estimates. Clin Infect Dis 2014; 58:319-27.
9. CDC. Interim adjusted estimates of seasonal influenza vaccine effectiveness-United States, February 2013. MMWR Morb Mortal Wkly Rep 2013; 62:119-23.
10. Blanton L, Alabi N, Mustaquim D, et al. Update: Influenza activity in the United States during the 2016-17 season and composition of the 2017-18 influenza vaccine. MMWR Morb Mortal Wkly Rep 2017; 66:668-76.
11. Flannery B, Chung JR, Thaker SN, et al. Interim estimates of 2016-17 seasonal influenza vaccine effectiveness: United States, February 2017. MMWR Morb Mortal Wkly Rep 2017; 66:167-71.
12. Gaglani M, Pruszynski J, Murthy K, et al. Influenza vaccine effectiveness against 2009 pandemic influenza A(H1N1) virus differed by vaccine type during 2013-2014 in the United States. J Infect Dis 2016; 213:1546-56.
13. Grohskopf LA, Sokolow LZ, Broder KR, Walter EB, Fry AM, Jernigan DB. Prevention and control of seasonal influenza with vaccines: Recommendations of the advisory committee on immunization practices-United States, 2018-19 influenza season. MMWR Recomm Rep 2018; 67:1-20.
14. Grohskopf LA, Sokolow LZ, Broder KR, et al. Prevention and control of seasonal influenza with vaccines. MMWR Recomm Rep 2016; 65:1-54.
15. WHO Global Influenza Surveillance Network. Serological diagnosis of influenza by haemagglutination inhibition testing: Manual for the laboratory diagnosis and virological surveillance of influenza. Geneva, Switzerland: World Health Organization, 2011.
16. Matrosovich M, Matrosovich T, Carr J, Roberts NA, Klenk HD. Overexpression of the alpha-2, 6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors. J Virol 2003; 77:8418-25.
17. Katz JM, Hancock K, Xu X. Serologic assays for influenza surveillance, diagnosis and vaccine evaluation. Expert Rev Anti Infect Ther 2011; 9:669-83.
18. Jackson ML, Nelson JC. The test-negative design for estimating influenza vaccine effectiveness. Vaccine 2013; 31:2165-8.
19. Rolfes M, Foppa I, Garg S, Flannery B, Brammer L, Singleton J. Estimated influenza illnesses, medical visits, hospitalizations averted by vaccination in the United States. Available at: Https://www.cdc.gov/flu/about/disease/2016-17.htm. Accessed 24 September 2018.
20. Rolfes M, Foppa I, Garg S, et al. Estimated influenza illnesses, medical visits, hospitalizations, deaths averted by vaccination in the United States. Available at: Https://www.cdc.gov/flu/about/disease/2015-16.htm. Accessed 13 March 2018.
21. Pebody R, Warburton F, Ellis J, et al. End-of-season influenza vaccine effectiveness in adults and children, United Kingdom, 2016/17. Euro Surveill 2017; 22:pii=17-00306.
22. Kissling E, Rondy M, I-MOVE/I-MOVE+ study team. Early 2016/17 vaccine effectiveness estimates against influenza A(H3N2): I-MOVE multicentre case control studies at primary care and hospital levels in Europe. Euro Surveill 2017; 22:pii=30464.
23. Skowronski DM, Chambers C, Sabaiduc S, et al. Interim estimates of 2016/17 vaccine effectiveness against influenza A(H3N2), Canada, January 2017. Euro Surveill 2017; 22:30460.
24. Sullivan SG, Chilver MB, Carville KS, et al. Low interim influenza vaccine effectiveness, Australia, 1 May to 24 September 2017. Euro Surveill 2017; 22:pii=17-00707.
25. Recommended composition of influenza virus vaccines for use in the 2017-2018 northern hemisphere influenza season. Weekly Epidem Rec 2017; 92:117-28.
26. Wu NC, Zost SJ, Thompson AJ, et al. A structural explanation for the low effectiveness of the seasonal influenza H3N2 vaccine. PLoS Pathog 2017; 13:e1006682.
27. Zost SJ, Parkhouse K, Gumina ME, et al. Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains. Proc Natl Acad Sci USA 2017; 114:12578-83.
28. Dunkle LM, Izikson R, Patriarca P, et al.; PSC12 Study Team. Efficacy of recombinant influenza vaccine in adults 50 years of age or older. N Engl J Med 2017; 376:2427-36.
29. Yang H, Carney PJ, Chang JC, Guo Z, Villanueva JM, Stevens J. Structure and receptor binding preferences of recombinant human A(H3N2) virus hemagglutinins. Virology 2015; 477:18-31.
30. Recommended composition of influenza virus vaccines for use in the 2018 southern hemisphere influenza season. Weekly Epidem Rec 2017; 92:625-48.